Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer Patents to Shanghai GenePharma

NEW YORK (GenomeWeb News) – Alnylam Pharmaceuticals announced today that it has granted a non-exclusive, worldwide license to Shanghai GenePharma, allowing the Chinese siRNA supplier to manufacture and sell RNAi products and services covered by Alnylam-owned patents for research purposes.
Alnylam owns exclusive rights to many RNAi structural properties and applications — for instance, in mammalian cells — under the Kreutzer-Limmer patent family. This license allows Shanghai GenePharma to provide these research tools to the pharmaceutical and research community in China and beyond.
As of last October, Alnylam had licensed its intellectual property to three other research product suppliers in Asia and 15 worldwide. That number has now climbed to more than 16 license agreements, according to Alnylam Vice President of Business Development Jason Rhodes.
“Providing this license to Shanghai GenePharma represents our first business transaction in China, which is regarded as having one of the fastest growing life science markets in the world,” Rhodes said in a statement.
Financial terms of the agreement were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.